Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.

Butler AM, Cetin K, Hernandez RK, Diane Reams B, Overman RA, I Kim J, Hirsch BR, Abernethy AP, Liede A, Alan Brookhart M.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):229-238. doi: 10.1002/pds.4360. Epub 2018 Jan 7.

PMID:
29316026
2.

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ.

Cancer Invest. 2017 May 28;35(5):333-344. doi: 10.1080/07357907.2017.1289215. Epub 2017 Apr 3.

PMID:
28368708
3.

Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.

Hirsch BR, Locke SC, Abernethy AP.

J Oncol Pract. 2016 Apr;12(4):e350-8. doi: 10.1200/JOP.2015.005090. Epub 2016 Mar 29.

4.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH.

JAMA Oncol. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315.

5.

Sequential Therapy in Metastatic Renal Cell Carcinoma.

Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ.

J Kidney Cancer VHL. 2016 Apr 5;3(1):23-35. doi: 10.15586/jkcvhl.2016.46. eCollection 2016. Review.

6.

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.

J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1.

PMID:
26330533
7.

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.

Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH.

JAMA Oncol. 2015 May;1(2):158-66. doi: 10.1001/jamaoncol.2015.43.

PMID:
26181015
8.

Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.

Hess CN, Roe MT, Clare RM, Chiswell K, Kelly J, Tcheng JE, Hagstrom E, James SK, Khouri MG, Hirsch BR, Kong DF, Abernethy AP, Krucoff MW.

J Am Heart Assoc. 2015 Jul 6;4(7). pii: e001779. doi: 10.1161/JAHA.115.001779.

9.

Deferred systemic therapy in patients with metastatic renal cell carcinoma.

Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ.

Clin Genitourin Cancer. 2015 Jun;13(3):e159-66. doi: 10.1016/j.clgc.2014.12.017. Epub 2014 Dec 31.

PMID:
25770767
10.

Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.

Dinan MA, Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2015 Jan;13(1):e1-7. Review.

PMID:
25583775
11.

The impact of specialty pharmaceuticals as drivers of health care costs.

Hirsch BR, Balu S, Schulman KA.

Health Aff (Millwood). 2014 Oct;33(10):1714-20. doi: 10.1377/hlthaff.2014.0558.

PMID:
25288414
12.

Biosimilars: a cure to the U.S. health care cost conundrum?

Hirsch BR, Lyman GH.

Blood Rev. 2014 Nov;28(6):263-8. doi: 10.1016/j.blre.2014.08.003. Epub 2014 Sep 16. Review.

PMID:
25260225
13.

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

Med Oncol. 2014 Sep;31(9):156. doi: 10.1007/s12032-014-0156-8. Epub 2014 Aug 14.

PMID:
25115744
14.

Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?

Hirsch BR, George DJ, Harrison MR.

Clin Adv Hematol Oncol. 2014 Mar;12(3):163-71. Review.

PMID:
24927264
15.

Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.

Mitchell AP, Hirsch BR, Abernethy AP.

Trials. 2014 Mar 25;15:92. doi: 10.1186/1745-6215-15-92.

16.

A comparison of FDA and EMA drug approval: implications for drug development and cost of care.

Howie LJ, Hirsch BR, Abernethy AP.

Oncology (Williston Park). 2013 Dec;27(12):1195, 1198-1200, 1202 passim. No abstract available.

17.

Comparative effectiveness research: moving medical oncology forward.

Hirsch BR, Zafar SY.

Semin Radiat Oncol. 2014 Jan;24(1):49-53. doi: 10.1016/j.semradonc.2013.08.005. Review.

PMID:
24314342
18.

Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.

Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

J Oncol Pract. 2014 Mar;10(2):e63-72. doi: 10.1200/JOP.2013.001180. Epub 2013 Nov 26.

PMID:
24281152
19.

Will biosimilars gain momentum?

Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1291-7. Review.

PMID:
24142828
20.

The ethics of health information technology in oncology: emerging isssues from both local and global perspectives.

LeBlanc TW, Shulman LN, Yu PP, Hirsch BR, Abernethy AP.

Am Soc Clin Oncol Educ Book. 2013:136-42. doi: 10.1200/EdBook_AM.2013.33.136. Review.

21.

The economics of new drugs: can we afford to make progress in a common disease?

Hirsch BR, Schulman KA.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e126. Review.

22.

Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov.

Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, Schulman KA, Dilts DM, Abernethy AP.

JAMA Intern Med. 2013 Jun 10;173(11):972-9. doi: 10.1001/jamainternmed.2013.627. Erratum in: JAMA Intern Med. 2013 Sep 9;173(16):1560.

PMID:
23699837
23.

Incorporating the patient's voice in the continuum of care.

Hirsch BR, Abernethy AP.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):116-8. No abstract available.

PMID:
23307987
24.

Conflict of interest disclosure in off-label oncology clinical trials.

Irwin B, Hirsch BR, Samsa GP, Abernethy AP.

J Oncol Pract. 2012 Sep;8(5):298-302. doi: 10.1200/JOP.2011.000523. Epub 2012 Jun 26.

25.

Leveraging informatics, mobile health technologies and biobanks to treat each patient right.

Hirsch BR, Abernethy AP.

Per Med. 2012 Nov;9(8):849-857. doi: 10.2217/pme.12.102.

PMID:
29776232
26.

Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Hirsch BR, Lyman GH.

Pharmacoeconomics. 2012 Jun 1;30(6):497-511. doi: 10.2165/11590130-000000000-00000. Review.

PMID:
22540394
27.

Structured decision-making: using personalized medicine to improve the value of cancer care.

Hirsch BR, Abernethy AP.

J Pers Med. 2012 Dec 27;3(1):1-13. doi: 10.3390/jpm3010001. Review.

28.

Delivering affordable cancer care in high-income countries.

Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M.

Lancet Oncol. 2011 Sep;12(10):933-80. doi: 10.1016/S1470-2045(11)70141-3.

PMID:
21958503
29.

Biosimilars: are they ready for primetime in the United States?

Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2011 Aug 1;9(8):934-42; quiz 943.

PMID:
21900222
30.

Informatics in action: lessons learned in comparative effectiveness research.

Hirsch BR, Giffin RB, Esmail LC, Tunis SR, Abernethy AP, Murphy SB.

Cancer J. 2011 Jul-Aug;17(4):235-8. doi: 10.1097/PPO.0b013e31822c3944. Review.

PMID:
21799331
31.

Capecitabine in the management of colorectal cancer.

Hirsch BR, Zafar SY.

Cancer Manag Res. 2011;3:79-89. doi: 10.2147/CMR.S11250. Epub 2011 Mar 24.

32.

Breast cancer screening with mammography.

Hirsch BR, Lyman GH.

Curr Oncol Rep. 2011 Feb;13(1):63-70. doi: 10.1007/s11912-010-0142-z. Review.

PMID:
21108025
33.

Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.

Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8186-91. Epub 2004 May 17.

34.

Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs.

Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA.

J Pharmacol Exp Ther. 2001 Aug;298(2):651-7.

PMID:
11454927
35.
36.

Comparison of pituitary-thyroid function in patients with endstage renal disease and in age- and sex-matched controls.

Davis FB, Spector DA, Davis PJ, Hirsch BR, Walshe JJ, Yoshida K.

Kidney Int. 1982 Feb;21(2):362-4.

37.

Synthesis of secretory component by colonic neoplasms.

Poger ME, Hirsch BR, Lamm ME.

Am J Pathol. 1976 Feb;82(2):327-38.

Supplemental Content

Loading ...
Support Center